● Recruiting

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Condition: Relapsed/Refractory Primary Central Nervous System Lymphoma · Sponsor: Ono Pharmaceutical Co., Ltd.

PhasePhase 3

Planned participants132

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Team · 888-724-3274 · clinicaltrials@deciphera.com

Always discuss trial participation with your own doctor first.

Locations (20)

Mayo Clinic Cancer Center	Phoenix, Arizona, United States	Recruiting
HonorHealth Cancer Center	Scottsdale, Arizona, United States	Recruiting
Providence Medical Foundation	Fullerton, California, United States	Recruiting
UC Irvine Health	Orange, California, United States	Recruiting
Yale Cancer Center	New Haven, Connecticut, United States	Recruiting
John Hopkins University	Washington D.C., District of Columbia, United States	Recruiting
Mayo Clinic Cancer Center	Jacksonville, Florida, United States	Recruiting
Massachusetts General Hospital	Boston, Massachusetts, United States	Recruiting
Beth Israel Deaconess Medical Center	Boston, Massachusetts, United States	Recruiting
Dana-Farber Cancer Institute	Boston, Massachusetts, United States	Recruiting
Mayo Clinic Cancer Center	Rochester, Minnesota, United States	Recruiting
Hackensack University Medical Center	Hackensack, New Jersey, United States	Recruiting

+ 8 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07104032